Please join us in congratulating the Astek Diagnostics team on its recent achievements and progress toward advancing its technology!

Astek is on a mission to bring its Jiddu Analyzer, a groundbreaking urine-based diagnostic tool, to market in 2025. The Jiddu Analyzer is designed to rapidly identify urinary tract infections and assess antibiotic sensitivity within just one hour, thereby reducing patient discomfort, complications, and healthcare costs.

Astek Co-founder and CEO Mustafa Al-Adhami said the vision for the device extends beyond UTIs and that the underlying technology has already been validated by the Astek team with three additional sample types — cerebrospinal fluid (CSF) with a focus on meningitis, effluent with a focus on surgical site infections, and blood with a focus on bacteremia.

Astek’s impressive recent milestones include:

She’s Independent Invests in Astek Diagnostics’ Pre-Series A Round 

On March 28, 2024, She’s Independent, a member-led angel investing group committed to promoting equitable opportunities and fostering positive change for women, announced a strategic investment in Astek Diagnostics’ Pre-Series A Round.

Astek Diagnostics Expands R&D Roadmap Through a Strategic Partnership with MRR Children’s Hospital

MRR Children’s Hospital (MRRCH) is a specialty pediatric hospital in Mumbai, India, renowned for its research initiatives. The partnership aims to address a significant challenge faced by MRRCH related to the treatment of acute bacterial meningitis. Astek’s Jiddu Analyzer will be deployed at MRRCH and its affiliated facilities to detect early signs of ABM in cerebrospinal fluid samples. The collaboration includes an accelerated pilot study starting in June 2024, focused on testing and validating the Jiddu Analyzer as applied to CSF samples.

Acceptance to MedTech Innovator’s 2024 Accelerator Cohort

MedTech Innovator is the world’s largest accelerator of medical technology companies. 2024 was a particularly competitive year, with around 1,300 companies globally applying for approximately 65 spots in this year’s cohort.

Already a graduate from Y Combinator’s S21 cohort, Astek will greatly benefit from spending the next four months with industry-leading corporate partners and industry experts as it ramps up its efforts to take its Jiddu Analyzer to market in 2025 and benefits millions of people globally.

TEDCO Invests in Astek Diagnostics

On April 15, TEDCO, Maryland’s economic engine for technology companies, announced a recent $250,000 Seed Funds investment in Astek Diagnostics, a biomedical company.